Skip to main content

Servier gets FDA clearance for Asparlas

12/26/2018
The Food and Drug Administration has approved Servier Pharmaceuticals’ Asparlas (calaspargase pegol-mknl).

Asparlas is an asparagine specific enzyme, as a component of a multi-agent chemotherapeutic regimen for acute lymphoblastic leukemia in pediatric and young adult patients aged 1 month to 21 years old.

This new product provides for a longer interval between doses compared to other available pegaspargase products.

The recommended calaspargase pegol-mknl dose is 2,500 units/m2 intravenously administered at a minimum dosing interval of every 21 days.
X
This ad will auto-close in 10 seconds